Truxima Injection, Solution
Product Images NDC 63459-103

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Truxima (NDC 63459-103). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cephalon, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Figure 1)

A Kaplan-Meier survival curve chart comparing progression-free survival probability over time (months) between Observation (red solid line) and Rituximab (blue dashed line) groups. The x-axis shows months up to 42, and the y-axis shows progression-free survival probability from 0 to 1. The number of participants at risk at various time points is listed below the x-axis for each group.*

FDA Label Image

Principal Display Panel (100mg Vial Carton)

A line graph showing the percent of ACR 20 responders over 24 weeks. The x-axis represents time in weeks and the y-axis shows the percentage of responders. Two lines compare placebo and rituximab-treated groups, with rituximab labeled as 2x1000 mg and placebo with sample sizes indicated.*

FDA Label Image

Principal Display Panel (500 mg Vial Carton)

A Kaplan-Meier survival curve comparing the percentage of patients with first major relapse over survival time in months for two treatments: Azathioprine (red dashed line) and Rituximab (blue solid line). The graph includes a table below showing the number of subjects with major relapse and at risk for each treatment over time.*

FDA Label Image

Figure 4

Truxima (rituximab-abbs) injection label showing 100 mg/10 mL concentration (10 mg/mL) for intravenous use after dilution. The label notes it is a single-dose vial and instructs discarding unused portions. It includes a pharmacist notice to provide the enclosed medication guide. The labeler is Cephalon, Inc., and the label displays the Teva logo.*

FDA Label Image

Figure 5

Truxima (rituximab-abbs) Injection 500 mg/50 mL (10 mg/mL) solution for intravenous use. The label indicates it is a single-dose vial to be used after dilution. The label includes a pharmacist instruction to provide the enclosed medication guide to the patient. Labeler is Cephalon, Inc. The NDC is 63459-104-50.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.